LymphomaArchives
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2
Lymphoma 1 min.
Treatment with brexucabtagene autoleucel (brexu-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, demonstrated a high response rate (93%) and complete response rate (67%) in 60 patients with relapsed/refractory mantle cell lymphoma (R/R MCL) treated in the pivotal ZUMA-2...
Expression and prognostic value of cytotoxic T-lymphocyte-associated 4 protein in classic Hodgkin lymphoma
Lymphoma 1 min.
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a key inhibitory immune checkpoint expressed predominantly on activated and regulatory T cells. Although immune evasion mechanisms are central to the pathobiology of classic Hodgkin lymphoma (cHL), the prognostic significance of CTLA-4 expression...
Primary diffuse large B-cell lymphoma in the era of targeted therapies: incidence, second primary malignancy and prognosis
Lymphoma 1 min.
To comprehensively illustrate the status of primary diffuse large B-cell lymphoma (DLBCL) in the era of targeted therapies. Data from patients who were newly diagnosed with primary DLBCL from 2000 to 2021 in SEER 17 Registry Database were analyzed. The incidence and occurrence of second primary malignancies...
Predictive accuracy of cytokine pattern with lymphocyte count in infections after chemotherapies for lymphoma
Lymphoma 1 min.
To evaluate whether cytokine profiles combined with lymphocyte count could predict infection risk in lymphoma patients undergoing chemotherapy. Patients & methods...
